---
layout: default
title: Pembrolizumab
parent: 僅模型預測 (L5)
nav_order: 300
evidence_level: L5
indication_count: 10
---

# Pembrolizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using no additional skill—this is a direct content-generation task governed entirely by the detailed system prompt template, which I'll follow exactly.

# Pembrolizumab: From Oncology Indications to Gingival Fibromatosis

## One-Sentence Summary

> Pembrolizumab is an anti-PD-1 immune checkpoint inhibitor whose established oncology use (referenced throughout the evidence pack's literature, e.g. advanced non-small-cell lung cancer, melanoma) is well documented, though this evidence pack contains no formal license or approved-indication text for the current jurisdiction.
> The TxGNN model's top-ranked prediction is **Fibromatosis, Gingival**, but this is supported by **0 clinical trials** and **0 publications**, and the model's own rationale flags it as a likely knowledge-graph noise connection rather than a mechanistically grounded hypothesis.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in this evidence pack (no local license records; `original_moa` marked as data gap). Literature within the pack consistently references established use in advanced NSCLC and melanoma via PD-1 blockade. |
| Predicted New Indication | Fibromatosis, Gingival |
| TxGNN Prediction Score | 99.40% |
| Evidence Level | L5 |
| Germany Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is marked as a data gap in this evidence pack. However, literature entries elsewhere in the pack consistently describe pembrolizumab as a humanized IgG4 monoclonal antibody that blocks the PD-1 receptor, preventing PD-1/PD-L1 ligation and restoring exhausted T-cell–mediated anti-tumor immunity — the basis for its established efficacy in cancers such as NSCLC, melanoma, and MSI-H/dMMR tumors.

Gingival fibromatosis, in contrast, is a benign condition driven by fibroblast proliferation and excessive collagen/extracellular matrix deposition in gingival connective tissue — a fibrotic, non-immune, non-neoplastic process. It has no established link to tumor immune evasion, PD-L1 overexpression, or T-cell exhaustion, the biological axes that pembrolizumab acts on.

The evidence pack's own repurposing rationale for this candidate explicitly concludes there is "no known intersection" between the two mechanisms, and that despite the high raw TxGNN score, the complete absence of any supporting clinical trial or literature evidence points to this being an indirect or noisy connection within the knowledge graph rather than a genuine biological signal. This assessment is corroborated by the fact that no publications or trials — even loosely related ones — were retrievable for this pairing.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Germany Market Information

No marketing authorizations were found for this drug in the current dataset (market status: Not Marketed, total authorizations: 0).

---

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Immunotherapy (anti-PD-1 immune checkpoint inhibitor, IgG4 monoclonal antibody) — not a conventional cytotoxic chemotherapy agent |
| Myelosuppression Risk | Low — as a checkpoint inhibitor rather than a classic cytotoxic agent, direct bone marrow suppression is not a characteristic toxicity; the dominant risk profile is immune-related adverse events (irAEs) rather than myelosuppression |
| Emetogenicity Classification | Minimal — immune checkpoint inhibitors are generally classified as minimally emetogenic as a drug class |
| Monitoring Items | Please refer to the package insert warnings and precautions (no drug-specific monitoring data provided in this evidence pack) |
| Handling Protection | Please refer to the package insert warnings and precautions (no drug-specific handling data provided in this evidence pack) |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked candidate carries a high raw TxGNN score but zero supporting clinical trials or literature, and the model's own mechanistic rationale identifies it as a probable knowledge-graph artifact with no biological plausibility linking PD-1 blockade to a benign fibrotic gingival condition.

**To proceed, the following is needed:**
- Confirmed mechanism-of-action documentation (currently a Blocking/High-severity data gap)
- TFDA/BfArM label warnings and contraindications (currently a Blocking data gap)
- Independent literature/pathology review to determine whether any PD-L1 or immune-mediated component exists in refractory gingival fibromatosis before further scoring
- Note: other candidates in this evidence pack — *lung hilum carcinoma* (L4, S1, Research Question) and *lung germ cell tumor* (L3, S1, Research Question) — carry stronger mechanistic and literature support and may warrant evaluation ahead of this top-ranked candidate
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

